神经分泌生物科学公司已启动一项针对四岁以下经典先天性肾上腺皮质增生症(CAH)儿科患者的2期临床研究,以评估其候选药物Crinecerfont的疗效与安全性。
神经分泌生物科学公司已启动一项针对四岁以下经典先天性肾上腺皮质增生症(CAH)儿科患者的2期临床研究,以评估其候选药物Crinecerfont的疗效与安全性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.